Multicenter open-label study to evaluate efficacy of gadobutrol-enhanced cardiac magnetic resonance imaging (CMRI) for detection of significant coronary artery disease (CAD) in subjects with known or suspected CAD by a blinded image analysis

Trial Profile

Multicenter open-label study to evaluate efficacy of gadobutrol-enhanced cardiac magnetic resonance imaging (CMRI) for detection of significant coronary artery disease (CAD) in subjects with known or suspected CAD by a blinded image analysis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Gadobutrol (Primary)
  • Indications Atherosclerosis; Coronary artery disease
  • Focus Diagnostic use
  • Acronyms GadaCAD 1
  • Sponsors Bayer
  • Most Recent Events

    • 31 Jul 2017 Planned End Date changed from 31 Jul 2017 to 31 Aug 2017.
    • 21 Jun 2017 Planned End Date changed from 1 May 2017 to 31 Jul 2017.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top